After a chaotic week that has seen Amarin Corporation's stock value fall 60% and market analysts reduce its price target to a fifth of its initial $20, the Irish biopharmaceutical company reached for a solution with the announcement on Oct. 23 that it will slash its workforce by half globally. [...]
Want to keep reading?
Sign up for a trial to have full access to our articles for 7 days!
Have an account? Log in here:
Enter the email address associated with your account. We'll send you instructions to reset your password.
We’ve sent a link to to change your password.
Please check your inbox to reset your password securely and easily.
redirecting...
